Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

EORTC Melanoma Group

Research output: Contribution to journal › Article › peer-review

162 Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences